GU Cancers 2018 | Research highlights in nmCRPC: PROSPER and SPARTAN studies

Andrew Armstrong

In this video, Andrew Armstrong, MD, from Duke University, Durham, NC, talks about the potential of the PROSPER (NCT02003924) and SPARTAN (NCT01946204) Phase III trials for nonmetastatic castration-resistant prostate cancer. From the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA, Dr Armstrong points to limitations with current therapy, and how research into osteomimicry can help develop treatments that aim to cure bone metastases in these patients, rather than merely delaying the symptoms.

Transcript (edited for clarity):

The highlights in prostate cancer were definitely the two Phase III studies, the PROSPER study and the SPARTAN study, which looked at the early use of apalutamide or enzalutamide versus placebo in patients who did not yet have metastatic prostate cancer, but had castration-resistant, meaning their PSAs were going up, they were going up quickly.
These men are at high risk of progressing to bone metastases, and the remarkable finding was that both of these drugs significantly delayed metastatic progression, particularly symptomatic metastatic progression in the vast majority of men, and did so in a substantially prolonged way, so an additional two to three years of extra time these men had before metastatic disease developed.
I think it’s important to realize that all these men still developed metastatic disease over time, it’s not curing these men, these men still need to be followed very carefully and our data on osteomimicry suggests perhaps an additional therapy that may be suggested for these men to really prevent metastasis rather than delaying them.

Share this video